Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine

NCT04969276 PHASE2 COMPLETED Results posted

The main purpose of this Phase II study was to assess the safety and immunogenicity of a dose of Fluzone High-Dose (HD) Quadrivalent vaccine and a third dose or booster dose of Moderna coronavirus disease 19 (COVID-19) vaccine administered concomitantly or singly in adults 65 years of age and older having received their second dose of the 2-dose schedule of Moderna COVID-19 vaccine at least 5 months before enrollment in the study.

Details

Lead sponsor	Sanofi Pasteur, a Sanofi Company
Phase	PHASE2
Status	COMPLETED
Enrolment	306
Start date	Fri Jul 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Influenza Immunization
• Healthy Volunteers

Interventions

• Quadrivalent Inactivated Influenza High Dose
• COVID-19 mRNA Vaccine (nucleoside modified)

Countries

United States